. Author manuscript; available in PMC: 2016 Nov 1.

Published in final edited form as: Am Heart J. 2015 Jul 26;170(5):1033–1041.e1. doi: 10.1016/j.ahj.2015.07.023

Table 3.

Multivariate and Propensity-Matched Cox Regression Results.

Model

	Amiodarone
	Full Cohort		Propensity-Matched Cohort

	HR (95% CI) N=122,465	P	HR (95% CI) N=21,716	P
Unadjusted	1.11 (1.07–1.16)	<0.001	—	—
Age, sex, race	1.18 (1.14–1.23)	<0.001	—	—

Full model^*
All patients	1.01 (0.97–1.05)	0.51	1.02 (0.97–1.07)	0.45
Adherence (MPR)-adjusted^†	0.90 (0.85–0.94)	<0.001	1.12 (0.97–1.31)	0.13

eGFR group, mL/min/1.73m²
eGFR ≥ 90	1.00 (0.86–1.17)	0.97	1.10 (0.90–1.36)	0.35
eGFR 60–89	1.00 (0.94–1.07)	0.96	1.03 (0.95–1.13)	0.46
eGFR 45–59	0.97 (0.90–1.05)	0.50	0.95 (0.85–1.05)	0.28
eGFR 30–44	0.98 (0.90–1.07)	0.68	1.05 (0.94–1.18)	0.36
eGFR 15–29	1.01 (0.89–1.15)	0.87	0.98 (0.83–1.16)	0.82
eGFR <15	0.80 (0.58–1.09)	0.16	0.93 (0.63–1.35)	0.69
Dialysis	1.37 (1.02–1.86)	0.04	1.23 (0.84–1.80)	0.29

For full cohort, full models adjusted for age, sex, race, hypertension, stroke, heart failure, diabetes mellitus, CHADS2 score, Charlson comorbidity score, digoxin, beta blockers, diuretics, anti-platelet agents, warfarin, statins, niacin/fibrates, ACE inhibitors/angiotensin receptor blockers, and eGFR group.

^†

Full adherence (MPR)-adjusted model was created by adjusting for amiodarone medication possession ratio (MPR) from date of first AF diagnosis to date of death or censoring, as a time-varying exposure. Also adjusted for age, sex, race, hypertension, stroke, heart failure, diabetes mellitus, CHADS2 score, Charlson comorbidity score, digoxin, beta blockers, diuretics, anti-platelet agents, warfarin, statins, niacin/fibrates, ACE inhibitors/angiotensin receptor blockers, and eGFR group.